Trials / Terminated
TerminatedNCT00544271
Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.
Phase IIIb Study to Evaluate Immunogenicity, Antibody Persistency and Reactogenicity of DTPa - INFANRIX and dTpa - BOOSTRIX Vaccines Administered to Healthy Children Previously Primed With 3 Doses of DTPa Vaccine Compared to Placebo (HAVRIX®JUNIOR)
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 720 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Months – 20 Months
- Healthy volunteers
- Accepted
Summary
To evaluate the immunogenicity, persistence of antibodies and reactogenicity of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX), when administered to subjects 18-20 months old, compared with not giving a booster DTP vaccine at 18-20 months. Study double blinded for the two DTP vaccines and single blinded for the control arm.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | INFANRIX | |
| BIOLOGICAL | BOOSTRIX | |
| BIOLOGICAL | HAVRIX |
Timeline
- Start date
- 2003-05-01
- Completion
- 2004-01-01
- First posted
- 2007-10-16
- Last updated
- 2016-09-07
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT00544271. Inclusion in this directory is not an endorsement.